RomanPerez-SolerMD

PubMed

• 250 citations
  Seroconversion rates following COVID-19 vaccination among patients with cancer.
  , , , , , , , , , , , , , , , , , , , , , > ;Cancer Cell. 2021 Aug 9
• 8 citations
  First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
  Haiying Cheng, Yiyu Zou, Chirag D. Shah, Ni Fan, Tushar D. Bhagat, Rasim Gucalp, Mimi Y. Kim, Amit Verma, Bilal Piperdi, Simon D. Spivack, Balazs Halmos, Roman Perez-S...> ;Lung Cancer. 2021 Apr 1
• 19 citations
  Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice.
  Aditi P. Singh, Elaine Shum, Lakshmi Rajdev, Haiying Cheng, Sanjay Goel, Roman Perez-Soler, Balazs Halmos> ;Cancers. 2020 May 4
• 531 citations
  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.
  Vikas Mehta, Sanjay Goel, Rafi Kabarriti, Daniel Cole, Mendel Goldfinger, Ana Acuna-Villaorduna, Kith Pradhan, Raja Thota, Stan H. Reissman, Joseph A. Sparano, Benjami...> ;Cancer Discovery. 2020 May 1
• 9 citations
  Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.
  Haiying Cheng, H. Dean Hosgood, Lei Deng, Kenny Ye, Christopher Su, Janaki Sharma, Yuanquan Yang, Balazs Halmos, Roman Perez-Soler> ;Clinical Lung Cancer. 2020 Mar 1
• 7 citations
  Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved Community.
  Christopher Su, Vincent Chau, Balazs Halmos, Chirag D. Shah, Rasim Gucalp, Stuart H. Packer, Kevin Wilson, Bruce D. Rapkin, Roman Perez-Soler, Haiying Cheng> ;American Journal of Clinical Oncology. 2019 Mar 1
• 40 citations
  Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence
  Diego Adrianzen Herrera, Nadia Ashai, Roman Perez-Soler, Haiying Cheng> ;Expert Opinion on Pharmacotherapy. 2019 Jan 1
• 9 citations
  Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community.
  Christopher Su, Amit Bhargava, Chirag D. Shah, Balazs Halmos, Rasim Gucalp, Stuart H. Packer, Nitin Ohri, Linda B. Haramati, Roman Perez-Soler, Haiying Cheng> ;Clinical Lung Cancer. 2018 Sep 1
• 12 citations
  Mouse models in squamous cell lung cancer: impact for drug discovery.
  Aditi P. Singh, Diego Adrianzen Herrera, Yifei Zhang, Roman Perez-Soler, Haiying Cheng> ;Expert Opinion on Drug Discovery. 2018 Feb 15
• 60 citations
  Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
  Haiying Cheng, Alain C. Borczuk, Murali Janakiram, Xiaoxin Ren, Juan Lin, Amer Assal, Balazs Halmos, Roman Perez-Soler, Xingxing Zang> ;Clinical Cancer Research. 2018 Apr 15
• 150 citations
  Leptomeningeal metastases in non-small-cell lung cancer.
  Haiying Cheng, Roman Perez-Soler> ;The Lancet. Oncology. 2018 Jan 1
• 105 citations
  Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
  Heather A. Wakelee, Suzanne E. Dahlberg, Steven M. Keller, William Tester, David R. Gandara, Stephen L. Graziano, Alex A. Adjei, Natasha B. Leighl, Seena C. Aisner, Ja...> ;The Lancet. Oncology. 2017 Dec 1
• 9 citations
  TRIB2 contributes to cisplatin resistance in small cell lung cancer.
  Yuanxin Liang, Dong Yu, Roman Perez-Soler, Jim Klostergaard, Yiyu Zou> ;Oncotarget. 2017 Nov 28
• Speaking the same language: a feasibility trial for a novel visual communication tool for oncologist-patient treatment discussions.
  Cristian Zanartu, Fernando J. Camacho, Nicole S. Nevadunski, Benjamin Martin, Noah Kornblum, Jennifer W. Chuy, Roman Perez-Soler> ;Psycho-Oncology. 2017 Jul 1
• 29 citations
  Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.
  C Hardin, Elaine Shum, Aditi P. Singh, Roman Perez-Soler, Haiying Cheng> ;Expert Opinion on Pharmacotherapy. 2017 Apr 17
• 5 citations
  Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
  Elaine Shum, Feng Wang, Salem Kim, Roman Perez-Soler, Haiying Cheng> ;Expert Opinion on Investigational Drugs. 2017 Mar 9
• 2 citations
  The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.
  Mark A. Socinski, Jamie E. Chaft, Benjamin Levy, Gregory J. Riely, Corey J. Langer, Roman Perez-Soler, Deborah L. Middleton, Linda Gracie-King, Laura M. Healy> ;Clinical Lung Cancer. 2017 May 1
• 19 citations
  18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
  Nitin Ohri, William Bodner, Balazs Halmos, Haiying Cheng, Roman Perez-Soler, Steven M. Keller, Shalom Kalnicki, Madhur Garg> ;International Journal of Radiation Oncology, Biology, Physics. 2017 Feb 1
• 11 citations
  Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
  Nitin Ohri, William Bodner, Rafi Kabarriti, Viswanathan Shankar, Haiying Cheng, Tony Abraham, Balazs Halmos, Rasim Gucalp, Roman Perez-Soler, Shalom Kalnicki, Madhur Garg> ;International Journal of Radiation Oncology, Biology, Physics. 2017 Jan 1
• 6 citations
  Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung C...
  Tianhong Li, Bilal Piperdi, William V. Walsh, Mimi Kim, Laurel A. Beckett, Rasim Gucalp, Missak Haigentz, Venu Bathini, Huiyu Wen, Kaili Zhou, Patricia Pasquinelli, Sr...> ;Clinical Lung Cancer. 2017 Jan 1
• 868 citations
  Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
  Roman Perez-Soler, Abraham Chachoua, Lisa A. Hammond, Eric K. Rowinsky, Mark S. Huberman, Daniel D. Karp, James Rigas, Gary M. Clark, Pedro Santabarbara, Philip Bonomi> ;Journal of Clinical Oncology. 2004 Aug 15
• 73 citations
  HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status
  Haiying Cheng, Murali Janakiram, Alain C. Borczuk, Juan Lin, Wanglong Qiu, Huijie Liu, Jordan M. Chinai, Balazs Halmos, Roman Perez-Soler, Xingxing Zang> ;Clinical Cancer Research. 2017 Feb 1
• 27 citations
  Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
  Jin S. Im, Amanda C. Herrmann, Chantale Bernatchez, Cara Haymaker, Jeffrey J. Molldrem, Waun Ki Hong, Roman Perez-Soler> ;Plos One. 2016 Jul 28
• 32 citations
  Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers
  Gloria Y.F. Ho, Siqun L. Zheng, Mary Cushman, Roman Perez-Soler, Mimi Y. Kim, Xiaonan Xue, Tao Wang, Nicolas F. Schlecht, Lesley F. Tinker, Thomas E. Rohan, Sylvia Was...> ;Journal of the National Cancer Institute. 2016 Jul 1
• 72 citations
  Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells
  Haiying Cheng, Zhenfeng Zhang, Ruth Rodriguez-Barrueco, Alain C. Borczuk, Huijie Liu, Jiyang Yu, Jose M. Silva, Simon K. Cheng, Roman Perez-Soler, Balazs Halmos> ;Oncotarget. 2016 May 17
• Join now to see all

Journal Articles

• Aerosol azacytidine inhibits orthotopic lung cancers in mice through its DNA demethylation and gene reactivation effects  
  Qiu X, Liang Y, Sellers R, Verma A, Perez-Soler R, Zou Y, PLoS ONE, 1/1/2014
• Talactoferrin alfa versus placebo in patients with refractory advanced non-small cell lung cancer (FORTIS-M trial)  
  Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, et al, Ann Oncol, 1/1/2013
• Role of erlotinib in the treatment of NSCLC: clinical outcomes in wild-type EGFR patients  
  Piperdi B, Perez-Soler R, Drugs, 1/1/2012
• Phase I/II study of bortezomib in combination with carboplatin and bevacizumab as first line therapy in patiernts with advanced non-small cell lung cancer  
  Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L, Perez-Soler R, J Thoracic Oncol, 1/1/2012
• Mechanisms of Resistance to VEGF Blockade  
  Abdullah SE, Perez-Soler R, Cancer, 1/1/2011
• Both gene amplification and allelic loss occur at 14q133 in lung cancer  
  Lutz D, Tian J, Kajiyama Y, Sapkar J, Perez-Soler R, Keller S, Lopez-Barcons L, Locker J, Clin Cancer Res, 1/1/2011
• Bortezomib: understanding the mechanism of action  
  Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R, Mol Cancer Ther, 1/1/2011
• Treatment of non-small cell lung cancer with erlotinib or gefitinib  
  Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A, New Engl J Med, 1/1/2011
• Intratracheal administration of 5-azacitidine avoids systemic toxicity and enhances antitumor efficacy in orthotopic human NSCLC xenograft models  
  Mahesh S, Ling Y, Perez-Soler R, Zou Y, Clin Lung Cancer, 1/1/2010
• Intercalation of erlotinib and pemetrexed in the treatment of NSCLC  
  Li T, Lara PN, Mack PC, Perez-Soler R, Gandara DR, Curr Drug Targets, 1/1/2010
• EGFR TKI’s for advanced NSCLC: practical questions  
  Perez-Soler R, Oncology, 1/1/2010
• Phase II study of the proteasome inhibitor bortezomib (PS 341, velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)  
  Li T, Ho L, Piperdi B, Macapinlac M, Rigas J, Camacho FJ, Perez-Soler R, Gucalp R, J Thoracic Oncology, 6/11/2009
• Tunicamycin enhances the sensitivity of human NSCLC cells to erlotinib  
  Ling, YH, Li T, Perez-Soler R, Haigentz M, Cancer Chemother Pharmacol, 1/1/2009
• Molecular pharmacodynamics of Irvalec® as single agent and in combination with Erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenog...  
  Ling Y, Aracil M, Perez-Soler R, Zou Y, Eur J Cancer, 1/1/2009
• Individualized therapy in NSCLC: future vs current clinical practice  
  Perez-Soler R, Oncogene, 1/1/2009
• Skin toxicities associated with epidermal growth factor inhibitors  
  Li T, Perez-Soler R, Target Oncology, 1/1/2009
• PI3KCA/PTEN mutation status predicts response of colon cancer cells to the EGFR inhibitor cetuximab  
  Jhawer M, Goel S, Ling YH. Augenlicht L, Perez-Soler R, Mariadason J, Cancer Res, 1/1/2008
• Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human NSCLC cells expressing wild type EGFR gene  
  Li T, Ling YH, Perez-Soler, R, J Thoracic Oncology, 1/1/2008
• Erlotinib induces apoptotsis via mitochondria-mediated pathways by oxidative phosphorylation-dependent activation of Bax/Bak  
  Ling YH, Haigentz M, Perez-Soler R, Mol Pharmacol, 1/1/2008
• Erlotinib, an effective EGFR tyrosine kinase inhibitor induces p27KIPI upregulation and nuclear translocation in association with cell growth inhibition and cell cycle...  
  Ling YH, Li T, Yuan Z, Haigentz M, Weber TK, Perez-Soler R, Mol Pharmacol, 4/24/2007
• Targeting protein translation in human NSCLC via combined MEK and mTOR suppression  
  Legrier ME, Yang CPH, Yan HG, Lopez-Barcons L, Keller SM, Perez-Soler R, Horwitz S, McDaid H, Cancer Res, 1/1/2007
• Development of an aerosol formulation of the p53 gene with low toxicity and high efficacy in the treatment of early lung cancer  
  Zou Y, Tornos C, Qiu X, Lia M, Perez-Soler R, Clin Cancer Res, 1/1/2007
• Erlotinib: recent results and future developments  
  Perez-Soler R, Clin Cancer Res, 1/1/2007
• Novel agents in the treatment of lung cancer: Fourth Cambridge Conference  
  Lynch TJ, Bonomi PD, Butts C, Perez-Soler R, et al, Clin Cancer Res, 1/1/2007
• Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung  
  Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicolson S, Peters GJ, Postmus PE, Clin Cancer Res, 1/1/2007
• Join now to see all

Books/Book Chapters

• Malignant Mesothelioma. 
  Chapter: Intracavitary therapies for malignant pleural mesothelioma. 
  Page 631 - 637Piperdi B, Shin DM, Perez-Soler REditors: Pass HI, Vogelzang NJ, Carbone M.Springer, New York, NY2005
• Lung Cancer, Methods in Molecular Medicine Series 
  Chapter: Chemopreventive therapeutics: Inhalation therapies for lung cancer and bronchial premalignancy. 
  Page 771 - 780Haigentz M, Perez-Soler REditors: Driscoll B.Humana Press, Totowa, NJ2002
• Cancer Treatment 
  Chapter: Investigational drugs. 
  Page 475 - 482Perez-Soler R, Muggia FMEditors: Haskell CM.W.B. Saunders Company, Philladelphia, PAEdition 5th,2001
• Medical Applications of Liposomes. 
  Chapter: Liposomes as carriers of hydrophobic antitumor agents. 
  Page 283 - 296Perez-Soler R, Zou YEditors: Lasic DD, Papahadjopoulos D.Elsevier1998
• Lung Cancer. 
  Chapter: Growth factors receptors as a target for therapy. 
  Page 309 - 341Perez-Soler R, Mendelsohn JEditors: Roth JA, Cox JD, Hong WK.Blackwell Science, Inc., Cambridge, MA1998
• EGF Receptor in tumor growth and progression. 
  Chapter: Epidermal growth factor receptor expression in head and neck tumorigenesis and saturation of EGFR with monoclonal antibody RG83852. 
  Shin DM, Perez-Soler R, Hittelman WN, Hong WKEditors: RB Lichtner, and RN Harkins.Springer-Verlag, Heidelberg1997
• Carbohydrates: Targets for Rational Drug Design. 
  Chapter: Sugar-modified anthracyclines: a search for drugs able to overcome multidrug resistance. 
  Priebe W, Perez-Soler REditors: Z.J. Witczak and K.A. Nieforth.Marcel Dekker Inc., New York, NY1996
• Anthracycline antibiotics: new analogs, methods of delivery and mechanisms of action. 
  Chapter: Non-cross resistant anthracyclines with reduced basicity and increased stability of the glycosidic bond. 
  Page 14 - 46Priebe W, Skibicki P, Varela O, Neamati N, Sznaidman M, Dziewiszek K, Grynkiewicz G, Horton D, Zou Y, Ling YH, Perez-Soler REditors: Priebe W.ACS Symposium, Washington, DC1995
• Anthracycline antibiotics: new analogs, methods of delivery and mechanisms of action. 
  Chapter: Use of drug carriers to ameliorate the antitumor properties of anthracycline antibiotics. 
  Page 300 - 319Perez-Soler R, Sugarman S, Zou Y, Priebe WEditors: Priebe W.ACS Symposium, Washington, DC1995
• Liposome-mediated cancer chemotherapy. 
  Chapter: The use of liposomes as delivery vehicles in biological systems. 
  Perez-Soler REditors: Sugarman S and Perez-Soler R.R.G. Landes Company, Austin, TX1995
• Drug Targeting and Delivery, Vol 2: Liposomes in drug delivery. 
  Chapter: Development of new lipophilic anticancer agents entrapped in liposomes. 
  Page 1 - 9Perez-Soler R, Khokhar AR, Priebe W, Krakoff IHEditors: Gregoriadis G, Florence AT and Patel HM.Harwood Academic Publishers, Chur, Switzerland1993
• Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. 
  Chapter: Pharmacological studies with new liposome-entrapped cisplatin derivatives. 
  Page 377 - 390Perez-Soler R, Siddik ZH, Vadiei K, Krakoff IH, Khokhar AREditors: Howell SB.Plenum Publishing Corporation, New York, NY1991
• From the bench to the bed side. Proceedings of the 16th International Congress of Chemotherapy 
  Chapter: Development of liposome entrapped platinum compounds. 
  Perez-Soler R, Khokhar ARJerusalem, Israel1989
• Liposomes in the treatment of infectious diseases and cancer. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 89. 
  Chapter: Design and development of liposome dependent antitumor agents. 
  Page 59 - 69Perez-Soler R, Lopez-Berestein G, Khokhar AREditors: Lopez-Berestein G, I Fidler.Alan Liss, Inc., New York, NY1988
• Liposomes as Drug Carriers. 
  Chapter: Development of lipophilic cisplatin analogues encapsulated in liposomes. 
  Page 401 - 417Perez-Soler R, Khokhar AR, Lopez-Berestein GEditors: G Gregoriadis.John Wiley & Sons, Ltd, United Kingdom1988
• Anticarcinogenesis and Radiation Protection. 
  Chapter: Prospects of Liposomes as Drug Carriers. 
  Page 441 - 450Lopez-Berestein G, Perez-Soler REditors: PA Cerutti, OF Nygaard, and MG Simic.Plenum Press, New York and London1987
• Join now to see all

Abstracts/Posters

• Role of EGFR inhibitors in the treatment of BAC. Oral Presentations Discussion
  Perez-Soler R, Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 6/1/2004

Lectures

• Demethylating Theerapy for Lung Cancer 
  Cancun, Mexico - 5/1/2014
• New Therapies for Lung Cancer 
  Mount Sinai School of Medicine - 3/1/2014
• Inhaled demethylating therapy. 
  Santa Barbara, CA - 2/1/2014
• 7th Annual New York Lung Cancer Symposium 
  Physicians' Education Resource, LLC, New York, New York - 11/10/2012
• The Molecular Biology of Lung Cancer 
  Fox Chase Cancer Center, Philadelphia, PA - 12/1/2011
• Maintenance and Frontline Therapy of NSCLC. 
  Sun Peaks, British Columbia, Canada - 2/1/2011
• Extending Survival with Erlotinib in NSCLC. 
  Seoul, South Korea - 12/1/2010
• Reversible EGFR inhibitors. 
  New York, NY - 11/1/2010
• Maintenance therapy in NSCLC: which agent? which patients? 
  New York, NY - 11/1/2010
• Advances in the treatment of NSCLC. 
  Rabin Medical Center, Hadassah Ein Kerem Medical Center, Israel - 11/1/2010
• Mechanisms of resistance to EGFR inhibitors. 
  Marbella, Spain - 6/1/2010
• Advances in Lung Cancer treatment. 
  Bologna, Italy - 6/1/2010
• Rationale for maintenance therapy in NSCLC. 
  Shanghai, China - 3/1/2010
• Use of biomarkers in lung cancer therapy. 
  Columbia College of Physicians and Surgeons, New York Presbyterian Hospital - 1/1/2010
• Breaking ground in the frontline treatment of NSCLC. 
  Hong Kong, China - 11/1/2009
• Mecanisms of resistance to EGFR inhibitors. 
  New York, NY - 11/1/2009
• Managament of skin toxicities secondary to EGFR inhibitors. 
  11/1/2009
• The Molecular Biology of Cancer 
  Ann Arbor, MI - 10/1/2009
• Management of side effects with new molecular therapies for NSCLC. 
  San Francisco, CA - 7/1/2009
• Advances in NSCLC treatment. 
  Roswell Park Memorial Institute - 7/1/2009
• How to get a Clinical RO1 grant? 
  Orlando, FL - 6/1/2009
• c-MET inhibitors in NSCLC. 
  HI - 6/1/2009
• Update on anti-EGFR monoclonal antibodies in the treatment of NSCLC. 
  HI - 6/1/2009
• What is new in second line therapy for NSCLC? 
  HI - 6/1/2009
• Advances in adjuvant therapy for NSCLC. 
  Fortaleza, Brazil - 2/1/2009
• Join now to see all

Other

• In vivo chemosensitivity screen for human tumors. 
  Perez-Soler R, US Patent 6,620,403
  9/16/2003
• Cryogenic and ultrasonic system and method of use in treating and removing tissue. 
  Kelman CD, Perez-Soler, R, US Patent 6,527,765 B2
  3/4/2003
• Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents. 
  Priebe, W, Perez-Soler, R, US Patent 6,437,105
  8/20/2002
• Submicron liposome suspensions obtained from preliposome lypophilizates. Licensed to Callisto Pharmaceuticals Inc, New York. In clinical development. 
  Zou Y, Priebe W, Perez-Soler R, US Patent 5,902,604
  5/11/1999
• Bis-anthracyclines with high activity against doxorubicin-resistant tumors. 
  Priebe W, Chaires JB, Przewloka T, Fokt I, Perez-Soler R, US Patent 5,874,412
  2/23/1999
• Formulation and use of carotenoids in the treatment of cancer. Licensed to Antigenics, Inc, New York. In clinical development. 
  Mehta K, Perez-Soler R, Lopez-Berestein G, Lenk RP, Hayman A, European Patent 0621773
  11/25/1998
• The liposomal entrapment of camptothecin. 
  Sugarman S, Poirot K, Perez-Soler R, US Patent 5,834,012
  11/10/1998
• Gene therapy of tumors using a non-viral delivery system. Filed, Claims allowed, Licensed to Transave Inc. Princeton, NJ 
  Zou Y, Perez-Soler, R
  1/6/1998
• Anthracyclines with unusually high activity against cells resistant to doxorubicin and analogs. 
  Priebe W, Skibicki P, Perez-Soler R, US Patent 5,625,043
  4/29/1997
• Stable liposomal formulations of lipophilic platinum compounds. Licensed to Antigenics Inc, New York. In clinical development. 
  Perez-Soler R, Khokhar AR, Han I, U.S. Patent 5,384,127
  1/24/1995
• Esters of 3'-desamino-doxorubicin, liposomal compositions thereof, and methods for their use. 
  Priebe W, Perez-Soler R, U.S. Patent 5,132,290
  7/21/1992
• Hydrophobic cis-platinum complexes efficiently incorporated into liposomes. 
  Khokhar AR, Lopez-Berestein G, Perez-Soler R, U.S. Patent 5,041,581
  8/20/1991
• Liposome compositions of anthracycline derivatives. 
  Perez-Soler R, Priebe W, Lopez-Berestein G, U.S. Patent 4,863,739
  9/5/1989
• Treatment of skin toxicity caused by EGFR inhibitors with phosphatase inhibitors. Licensed to Talon Therapeutics, South San Francisco, CA. In Phase II clinical develo... 
  Perez-Soler R, Ling YH, US Patent 7,745,494
• Join now to see all